The FOXP1 and NF-κB pathways work together to promote the growth of normal primary B cells as well as DLBCL B cells. In DLBCL patients, overall survival can be determined by the expression of a subset of 7 FOXP1 target genes. In the absence of NF-κB signaling, the survival benefit of FOXP1 is lost, indicating the importance of this pathway is most relevant in cells that rely on signaling pathways such as CD40, B-cell receptor (BCR), and Toll-like receptor (TLR) to maintain constitutive NF-κB activation.